אימנד 150 מ"ג IV

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

FOSAPREPITANT AS FOSAPREPITANT DIMEGLUMINE 150 MG

Commercializzato da:

MERCK SHARP & DOHME ISRAEL LTD

Codice ATC:

A04AD12

Forma farmaceutica:

POWDER FOR SOLUTION FOR INFUSION

Via di somministrazione:

I.V

Prodotto da:

MERCK SHARP & DOHME B.V, HOLLAND

Gruppo terapeutico:

APREPITANT

Indicazioni terapeutiche:

Emend IV 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose Cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Data dell'autorizzazione:

2011-11-01